(Reuters) -Merck said on Monday it expects a non-risk adjusted commercial opportunity in excess of $5 billion from Cidara Therapeutics’ experimental flu drug.
The drugmaker struck a deal worth nearly $9.2 billion last week to acquire Cidara to gain access to the long-acting antiviral drug, CD388, currently in late-stage trial.
(Reporting by Mariam Sunny in Bengaluru; Editing by Shilpi Majumdar)
Keyword: Text NEWS to 39327*
Details: Breaking News Alerts
Messages: expect up to 1 per week
Keyword: Text WEATHER to 39327*
Details: Daily Weather Forecast
Messages: expect up to 7 per week
Sponsor: King’s Campers
Keyword: Text TRAFFIC to 39327*
Details: Traffic and road alerts
Messages: expect up to 5 per week
*Message & data rates may apply. Text STOP to 39327 to quit. Text HELP for help or visit www.vibes.com/help/ for support. No purchase necessary. Marketing text messages generated by an automated dialer will be delivered to the phone number you provide at opt-in
Comments